NEW YORK – The National Institutes of Health's Rapid Acceleration of Diagnostics team has closed the submission process and earmarked $1.2 billion to support SARS-CoV-2 diagnostics from more than 40 labs and companies.
The final RADx portfolio of products to be developed and scaled includes a diversity of diagnostics from companies such as Illumina, Quidel, Fluidigm, and Mesa Biotech, and is likely to result in a near-term manufacturing boom in rapid antigen tests and over-the-counter home-use diagnostics.